Serina Therapeutics, Inc. (SER) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Serina Therapeutics, Inc. is a clinical-stage biotechnology company developing drug product candidates for neurological diseases and pain using its proprietary POZ drug delivery technology. The company completed a reverse recapitalization merger in March 2024. This report covers the quarterly period ended March 31, 2025. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenues | $0 | $5,000 |
| Net Loss | $(4.82) million | $(15.02) million |
| Net Loss Per Share (Basic/Diluted) | $(0.49) | $(5.38) |
| Operating Expenses | $5.86 million | $2.33 million |
| Cash and Cash Equivalents (End of Period) | $4.27 million | $8.76 million |
| Net Cash Used in Operating Activities | $(4.32) million | $(1.58) million |
| Net Cash Provided by Financing Activities | $4.92 million | $2.73 million |
| Warrant Liability | $2.59 million | $24.08 million |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $15.0 million in Q1 2024 to $4.8 million in Q1 2025. This improvement is primarily driven by a $13.7 million swing in "Other income (expense), net," shifting from a $12.7 million expense to a $1.0 million gain. This was due to the absence of fair value losses on convertible notes (which were converted in the 2024 merger) and a $1.0 million gain on the change in fair value of warrant liabilities.
- Operating Expense Increase: Total operating expenses rose 152% to $5.9 million. Research and Development (R&D) expenses increased by $1.8 million to $3.0 million, and General and Administrative (G&A) expenses increased by $1.7 million to $2.9 million. Increases were attributed to higher headcount, stock-based compensation, and professional fees.
- Liquidity Position: Cash balances decreased from $8.8 million in Q1 2024 to $4.3 million in Q1 2025, reflecting higher operating burn rates despite financing inflows.
Outlook, Risks, and Management Commentary
- Going Concern Doubt: Management has expressed substantial doubt about the company's ability to continue as a going concern. Current cash ($4.3 million) plus $5.0 million in proceeds from a private placement in April 2025 is not expected to fund operations through the first quarter of 2026.
- Capital Needs: The company anticipates needing additional financing to advance its lead product candidate, SER-252 (POZ-apomorphine), into Phase 1 clinical trials and to fund ongoing operations. Failure to secure capital could force delays or termination of development programs.
- Recent Financing: In April 2025, the company entered a Securities Purchase Agreement for the issuance of Series A convertible preferred stock, raising approximately $5.0 million.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting as of March 31, 2025, citing a lack of qualified accounting personnel and inadequate segregation of duties. A remediation plan is underway.
- Risks: Key risks include the uncertainty of clinical trial outcomes, regulatory approval, and the ability to raise additional capital on favorable terms.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $9.3 million total liquidity (cash on hand + April proceeds) against the projected burn rate to reach Q1 2026.
- Financing Terms: Review the terms of the April 2025 Series A convertible preferred stock, specifically the 8% dividend payable in common stock and conversion triggers.
- Internal Control Remediation: Monitor progress on the remediation plan for material weaknesses in financial reporting controls.
- Warrant Liability Volatility: Assess the impact of future stock price fluctuations on the $2.6 million warrant liability, which is marked-to-market and affects net income.
- Development Milestones: Track the timeline for the Investigational New Drug (IND) application submission for SER-252 and the initiation of Phase 1 trials.